Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Krista KinneerPhilipp WortmannZachary A CooperNiall J DickinsonLuke A MastersonThais CailleauIan HutchinsonBalakumar VijayakrishnanMary McFarlaneKathryn BallMichael DaviesArthur LewisYue HuangAnton I RosenbaumJiaqi YuanJon ChesebroughJudith AndertonNoel MonksSteven J NovickJixin WangNazzareno DimasiR James ChristieDarrin SabolFrances Anne TostoYann WallezElisabetta LeoMark R AlbertellaAnna D StaniszewskaDavid A TicePhilip W HowardNadia LuheshiPuja SapraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These data provide evidence for the potential utility of AZD8205 for treatment of B7-H4-expressing tumors and support the rationale for an ongoing phase 1 clinical study (NCT05123482).